Literature DB >> 16720837

Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.

Benjamin S Braun1, Joehleen A Archard, Jessica A G Van Ziffle, David A Tuveson, Tyler E Jacks, Kevin Shannon.   

Abstract

Somatic activation of a conditional targeted Kras(G12D) allele induces a fatal myeloproliferative disease in mice that closely models juvenile and chronic myelomonocytic leukemia. These mice consistently develop severe and progressive anemia despite adequate numbers of clonogenic erythroid progenitors in the bone marrow and expanded splenic hematopoiesis. Ineffective erythropoiesis is characterized by impaired differentiation. These results demonstrate that endogenous levels of oncogenic Ras have cell lineage-specific effects and support efforts to modulate Ras signaling for therapy of anemia in patients with myelodysplastic syndromes and myeloproliferative disorders.

Entities:  

Mesh:

Year:  2006        PMID: 16720837      PMCID: PMC1895533          DOI: 10.1182/blood-2006-01-013490

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

Authors:  David A Tuveson; Alice T Shaw; Nicholas A Willis; Daniel P Silver; Erica L Jackson; Sandy Chang; Kim L Mercer; Rebecca Grochow; Hanno Hock; Denise Crowley; Sunil R Hingorani; Tal Zaks; Catrina King; Michael A Jacobetz; Lifu Wang; Roderick T Bronson; Stuart H Orkin; Ronald A DePinho; Tyler Jacks
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

Review 2.  Role of the macrophage in erythropoiesis.

Authors:  Y Sadahira; M Mori
Journal:  Pathol Int       Date:  1999-10       Impact factor: 2.534

Review 3.  Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.

Authors:  Jennifer O Lauchle; Benjamin S Braun; Mignon L Loh; Kevin Shannon
Journal:  Pediatr Blood Cancer       Date:  2006-05-01       Impact factor: 3.167

4.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Marco Tartaglia; Charlotte M Niemeyer; Alessandra Fragale; Xiaoling Song; Jochen Buechner; Andreas Jung; Karel Hählen; Henrik Hasle; Jonathan D Licht; Bruce D Gelb
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

5.  A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.

Authors:  Eva Hellström-Lindberg; Nina Gulbrandsen; Greger Lindberg; Tomas Ahlgren; Inger Marie S Dahl; Ingunn Dybedal; Gunnar Grimfors; Eva Hesse-Sundin; Martin Hjorth; Lena Kanter-Lewensohn; Olle Linder; Michaela Luthman; Eva Löfvenberg; Gunnar Oberg; Anja Porwit-MacDonald; Anders Rådlund; Jan Samuelsson; Jon Magnus Tangen; Ingemar Winquist; Finn Wisloff
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

6.  Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Authors:  Iris T Chan; Jeffery L Kutok; Ifor R Williams; Sarah Cohen; Lauren Kelly; Hirokazu Shigematsu; Leisa Johnson; Koichi Akashi; David A Tuveson; Tyler Jacks; D Gary Gilliland
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

7.  Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Authors:  Benjamin S Braun; David A Tuveson; Namie Kong; Doan T Le; Scott C Kogan; Jacob Rozmus; Michelle M Le Beau; Tyler E Jacks; Kevin M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

8.  Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome.

Authors:  David P Steensma; Ayalew Tefferi; Chin-Yang Li
Journal:  Leuk Res       Date:  2003-09       Impact factor: 3.156

9.  Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.

Authors:  Mignon L Loh; Shashaank Vattikuti; Suzanne Schubbert; Melissa G Reynolds; Elaine Carlson; Kenneth H Lieuw; Jennifer W Cheng; Connie M Lee; David Stokoe; Jeannette M Bonifas; Nicole P Curtiss; Jason Gotlib; Soheil Meshinchi; Michelle M Le Beau; Peter D Emanuel; Kevin M Shannon
Journal:  Blood       Date:  2003-11-26       Impact factor: 22.113

10.  Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry-based novel culture system.

Authors:  Jing Zhang; Merav Socolovsky; Alec W Gross; Harvey F Lodish
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

View more
  26 in total

1.  USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism.

Authors:  Johanna Melo-Cardenas; Yuanming Xu; Juncheng Wei; Can Tan; Sinyi Kong; Beixue Gao; Elena Montauti; Gina Kirsammer; Jonathan D Licht; Jindan Yu; Peng Ji; John D Crispino; Deyu Fang
Journal:  Blood       Date:  2018-05-29       Impact factor: 22.113

2.  BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.

Authors:  Liping Zhang; Rajesh R Singh; Keyur P Patel; Francesco Stingo; Mark Routbort; M James You; Roberto N Miranda; Guillermo Garcia-Manero; Hagop M Kantarjian; L Jeffrey Medeiros; Rajyalakshmi Luthra; Joseph D Khoury
Journal:  Am J Hematol       Date:  2014-02-10       Impact factor: 10.047

Review 3.  Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development.

Authors:  Eva Chung; Motonari Kondo
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

4.  HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia.

Authors:  Boris Bartholdy; Maximilian Christopeit; Britta Will; Yongkai Mo; Laura Barreyro; Yiting Yu; Tushar D Bhagat; Ujunwa C Okoye-Okafor; Tihomira I Todorova; John M Greally; Ross L Levine; Ari Melnick; Amit Verma; Ulrich Steidl
Journal:  J Clin Invest       Date:  2014-03       Impact factor: 14.808

5.  Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

Authors:  Qing Li; Kevin M Haigis; Andrew McDaniel; Emily Harding-Theobald; Scott C Kogan; Keiko Akagi; Jasmine C Y Wong; Benjamin S Braun; Linda Wolff; Tyler Jacks; Kevin Shannon
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

6.  A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.

Authors:  Natalya Lyubynska; Matthew F Gorman; Jennifer O Lauchle; Wan Xing Hong; Jon K Akutagawa; Kevin Shannon; Benjamin S Braun
Journal:  Sci Transl Med       Date:  2011-03-30       Impact factor: 17.956

7.  Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Authors:  Gordon Chan; Demetrios Kalaitzidis; Tatiana Usenko; Jeffery L Kutok; Wentian Yang; M Golam Mohi; Benjamin G Neel
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

8.  K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Authors:  Thomas Kindler; Melanie G Cornejo; Claudia Scholl; Jianing Liu; Dena S Leeman; J Erika Haydu; Stefan Fröhling; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113

Review 9.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Authors:  Stephanie Beurlet; Christine Chomienne; Rose Ann Padua
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

10.  Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.

Authors:  Mona Meyer; Daniela Rübsamen; Robert Slany; Thomas Illmer; Kathleen Stabla; Petra Roth; Thorsten Stiewe; Martin Eilers; Andreas Neubauer
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.